Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
231.58
+3.22 (1.41%)
May 5, 2026, 10:02 AM EDT - Market open
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts that cover Ligand Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $256.29, which forecasts a 10.67% increase in the stock price over the next year. The lowest target is $220 and the highest is $289.
Price Target: $256.29 (+10.67%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 6 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $243 → $289 | Strong Buy | Maintains | $243 → $289 | +24.79% | Apr 30, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $235 → $252 | Buy | Maintains | $235 → $252 | +8.82% | Apr 28, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $276 → $282 | Strong Buy | Maintains | $276 → $282 | +21.77% | Apr 15, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $239 → $243 | Strong Buy | Maintains | $239 → $243 | +4.93% | Apr 14, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $270 → $276 | Strong Buy | Maintains | $270 → $276 | +19.18% | Mar 24, 2026 |
Financial Forecast
Revenue This Year
283.57M
from 268.09M
Increased by 5.78%
Revenue Next Year
359.74M
from 283.57M
Increased by 26.86%
EPS This Year
9.22
from 6.13
Increased by 50.46%
EPS Next Year
11.09
from 9.22
Increased by 20.29%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 308.4M | 418.8M | ||||||
| Avg | 283.6M | 359.7M | ||||||
| Low | 260.7M | 307.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 15.0% | 47.7% | ||||||
| Avg | 5.8% | 26.9% | ||||||
| Low | -2.8% | 8.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 10.36 | 13.63 | |||||
| Avg | 9.22 | 11.09 | |||||
| Low | 8.16 | 8.85 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 69.1% | 47.8% | |||||
| Avg | 50.5% | 20.3% | |||||
| Low | 33.2% | -4.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.